USPTO Report On COVID-19 Diagnostic Patent Applications

TC
Thompson Coburn LLP

Contributor

For almost 90 years, Thompson Coburn LLP has provided the quality legal services and counsel our clients demand to achieve their most critical business goals. With more than 380 lawyers and 40 practice areas, we serve clients throughout the United States and beyond.
Most of us have undergone some type of COVID-19 testing. This report on the origin and funding of COVID-19 diagnostic patent applications...
United States Intellectual Property

Most of us have undergone some type of COVID-19 testing. This report on the origin and funding of COVID-19 diagnostic patent applications illustrates the great inventive activity of small companies and universities. It will be interesting to see which of these technologies are improvements over available diagnostic methods and are potentially adopted.

The United States Patent and Trademark Office's (USPTO) Office of the Chief Economist released a report revealing that small companies and universities led the way in developing inventions to diagnose COVID-19, as evidenced by patent applications filed at the USPTO through April 2023.

The U.S. federal government helped spur this invention, with 10.7% of COVID-19 diagnostic public filings receiving support. The National Institutes of Health provided the most assistance (about 64%), while the National Science Foundation provided the second most, at 21.59%. Although COVID-19 diagnostic invention was highly concentrated in a few technologies, 8.6% of these inventions were also applicable to the treatment of COVID-19.

www.uspto.gov/...

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More